Last reviewed 2026-05-26 · How we verify

Taitacept

Beijing Tongren Hospital · Phase 2 active Small molecule ✓ Verified May 2026

Taitacept is a Small molecule drug developed by Beijing Tongren Hospital. It is currently in Phase 2 development. Also known as: No other Intervention Names.

Taitacept is being studied for the treatment of refractory or recurrent anti-NMDAR/anti-LGI1 encephalitis. The exact mechanism of Taitacept is not specified in the provided information, but it is being investigated for its efficacy and safety in treating this condition.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Taitacept
Also known as	No other Intervention Names
Sponsor	Beijing Tongren Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Taitacept CI brief — competitive landscape report
Taitacept updates RSS · CI watch RSS
Beijing Tongren Hospital portfolio CI

Frequently asked questions about Taitacept

What is Taitacept?

Taitacept is a Small molecule drug developed by Beijing Tongren Hospital.

Who makes Taitacept?

Taitacept is developed by Beijing Tongren Hospital (see full Beijing Tongren Hospital pipeline at /company/beijing-tongren-hospital).

Is Taitacept also known as anything else?

Taitacept is also known as No other Intervention Names.

What development phase is Taitacept in?

Taitacept is in Phase 2.

Manufacturer: Beijing Tongren Hospital — full pipeline
Therapeutic area: All drugs in Other
Also known as: No other Intervention Names

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing